Halil Komek, Hasan Morcalı, Serdar Altındağ, Canan Can, Timur Ugur

BIODISTRIBUTION OF Ga 68 PSMA IN NORMAL ORGANS OF PATIENTS WITH PROSTATE CARCINOMA

Background: There have been different biodistribution of Ga-68 PMSA in normal organs.Methods: SUVmax and SUVmean values was evuluated of 66 patients who underwent Ga-68 PSMA, without radical prostatectomy, relapse in the prostate gland, extensive metastasis, or metastasis in the target.Results: The SUVmax and SUVmean values of the patients included in the study were determined to range from high to low as bladder, kidney, submandibular gland, parotid salivary gland, duodenum 3rd part, jejunum, spleen, liver and lachrymal gland. The highest uptake was observed in the bladder, kidneys and salivary gland. Conclusions: High PSMA expressions were observed in the kidney, salivary glands and duodenum 3rd part, medium PSMA expressions were observed in the liver and lachrymal glands, low PSMA expressions were observed in normal prostate tissue, stomach, ileum and pancreas and no PSMA expression was observed in cerebral and cerebellar cortexes. The bladder should be emptied before examination and reporting and the proximal small bowel should be examined more carefully as it can show higher PSMA expression.

Keywords:

Prostate Cancer, Ga-68 PMSA, Biodistribution,

PDF

___

1. Silver DA, Pellicer I, Fair WR et al (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3:81–85
2. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcino ma and lymph node metastases. Urology 1998;52(4):637–40.
3. Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D,Mehes G. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res 2009;15(2):167–72.
4. Schuhmacher J, Maier-Borst W. A new 68Ge/68Ga radioisotope generator system for production of 68Ga in dilute HCl. Int J Appl Radiat Isot 1981;32:31–6.
5. Bander NH. Technology insight: monoclonal antibody imaging of prostate cancer. Nat Clin Pract Urol 2006;3(4):216–25
6. Afshar-Oromieh A, Haberkorn U, Eder M, Eisenhut M, Zechmann C. [(68)Ga]Gallium-labeled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with (18)F-FECH. Eur J Nucl Med Mol Imaging 2012;39(6):1085–6.
7. Eder M, Schafer M, Bauder-Wüst U, Hull WE, Wangler C, Mier W, et al. (68)Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PEt imaging. Bioconjug Chem 2012;23:688-97
8. Ghosh A, Heston WD. Tumor target prostate specific membraneantigen (PSMA) and its regulation in prostate cancer. J Cell Bio-chem 2004;91:528–39.
9. Human protein atlas. FOLH1. http://www.proteinatlas.org/ ENSG00000086205/normal.
10. Israeli R. S., Powell C.T., Corr J.G., Fair W.R., and Heston W.D.W.. Expression oft he prostate-specific membrane antigen. Cancer Res.,54: 1807-1811,1994.
11. Troyer J.K., Beckett M.L., and Wright G.L., Jr. Detection and characterization oft he prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int. J. Cancer, 62:552-558,1995.
12. Pinto J., Suffoletto B., Berzin T., Qaio C., Lin S., Tong W., and Heston W.D.W.. İdentification of a membrane-bound pteroyl poly gamma-glutamyl carboxypeptidase (folate hydrolase) that is highly expressed in human prostatic carcinoma cells (Abstract 2862). FASEB J., 10:A496,1996.